Cytochrome P450 pharmacogenetics in African populations: implications for public health

Ready to Put Metadata on the Post-2015 Development Agenda? Linking Data Publications to Responsible Innovation and Science Diplomacy

(2014) Vural Özdemir et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications

(2014) Eugene Kolker et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients

(2014) Britt I Drogemöller et al.   PHARMACOGENOMICS

The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients

(2013) Emile Bienvenu et al.   ANTIVIRAL RESEARCH

Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa

(2013) Ripudaman K Bains et al.   BMC GENETICS

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

(2013) Jackson K Mukonzo et al.   BMC INFECTIOUS DISEASES

Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study

(2013) Tyren M Dodgen et al.   BMC Medical Genetics

Cytochrome P450 pharmacogenetics in African populations

(2013) Marco Alessandrini et al.   DRUG METABOLISM REVIEWS

Mitochondrial DNA Subhaplogroups L0a2 and L2a Modify Susceptibility to Peripheral Neuropathy in Malawian Adults on Stavudine Containing Highly Active Antiretroviral Therapy

(2013) Elizabeth Kampira et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients

(2013) F. S. Sarfo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients

(2013) Marelize Swart et al.   Pharmacogenetics and Genomics

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

(2013) Eliford Ngaimisi et al.   PLoS One

CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis

(2013) Danny W. K. Lum et al.   PLoS One

Biomedical research, a tool to address the health issues that affect African populations

(2013) Emmanuel Peprah et al.   Globalization and Health

Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania

(2012) E. M. Staehli Hodel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients

(2012) Marelize Swart et al.   BMC Medical Genetics

Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations

(2012) Liang Jin Zuo et al.   Genetic Testing and Molecular Biomarkers

Warfarin Pharmacogenetics: Polymorphisms of theCYP2C9, CYP4F2, and VKORC1Loci in a Genetically Admixed Omani Population

(2012) Anil V. Pathare et al.   HUMAN BIOLOGY

Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1–Infected Children in Rwanda

(2012) Philippe R. Mutwa et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

(2012) P. Byakika-Kibwika et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

(2012) Emily R. Holzinger et al.   Pharmacogenetics and Genomics

Pharmacogenomics and Patient Care: One Size Does Not Fit All

(2012) K. M. Giacomini et al.   Science Translational Medicine

ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients

(2012) Marelize Swart et al.   Frontiers in Genetics

Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

(2011) Almudena Sánchez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacogenomic testing: Relevance in medical practice: Why drugs work in some patients but not in others

(2011) J. P. KITZMILLER et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

(2011) A. Habtewold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Absence Seizures Associated With Efavirenz Initiation

(2011) Renate Strehlau et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Genetic variants inCYP(-1A2,-2C9,-2C19,-3A4and-3A5),VKORC1andABCB1genes in a black South African population: a window into diversity

(2011) Collet Dandara et al.   PHARMACOGENOMICS

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study

(2011) G Yimer et al.   PHARMACOGENOMICS JOURNAL

Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population

(2010) Galen E. B. Wright et al.   ANNALS OF HUMAN GENETICS

Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?

(2010) William Kudzi et al.   BMC Medical Genetics

The Evolution of Human Genetic and Phenotypic Variation in Africa

(2010) Michael C. Campbell et al.   CURRENT BIOLOGY

Update Information on Drug Metabolism Systems— 2009, Part II. Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters

(2010) Slobodan Rendic et al.   CURRENT DRUG METABOLISM

African nations vow to support science

(2010) Linda Nordling   NATURE

Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus

(2010) Silvia Fuselli et al.   Pharmacogenetics and Genomics

CombinedCYP2C9,VKORC1andCYP4F2frequencies among racial and ethnic groups

(2010) Stuart A Scott et al.   PHARMACOGENOMICS

Working toward a synthesis of archaeological, linguistic, and genetic data for inferring African population history

(2010) L. B. Scheinfeldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

(2010) Verena Gounden et al.   AIDS Research and Therapy

Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients

(2009) S. E. Cabrera et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

(2009) William Kudzi et al.   BMC Medical Genetics

Generating Genome-Scale Candidate Gene Lists for Pharmacogenomics

(2009) N T Hansen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Discovery of Novel Functional Variants and Extensive Evaluation of CYP2D6 Genetic Polymorphisms in Koreans

(2009) S.-J. Lee et al.   DRUG METABOLISM AND DISPOSITION

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

(2009) Julia di Iulio et al.   Pharmacogenetics and Genomics

Genome-wide patterns of population structure and admixture in West Africans and African Americans

(2009) K. Bryc et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease Mapping

(2008) Michael C. Campbell et al.   Annual Review of Genomics and Human Genetics

The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements

(2008) Andrea Gaedigk et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Establishment of a biobank and pharmacogenetics database of African populations

(2008) Alice Matimba et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics

(2008) Giorgio Sirugo et al.   HUMAN GENETICS

The next steps for genomic medicine: challenges and opportunities for the developing world

(2008) Billie-Jo Hardy et al.   NATURE REVIEWS GENETICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Warfarin Pharmacogenetics

(2008) Nita A Limdi et al.   PHARMACOTHERAPY

Cytochrome P450 and Chemical Toxicology

(2007) F. Peter Guengerich   CHEMICAL RESEARCH IN TOXICOLOGY